Effect of JS001, a monoclonal antibody targeting programed death-1 (PD-1), on responses and disease control in patients with advanced or refractory alveolar soft part sarcoma: Results from a phase 1 trial.

Sheng Yang,Jianliang Yang,Xiaohong Han,Ying Han,Shiyu Jiang,Jiarui Yao,Zhishang Zhang,Shuxiang Zhang,Peng Liu,Yan Qin,Hui Feng,Sheng Yao,Sun Y,Yuankai Shi

Effect of JS001, a monoclonal antibody targeting programed death-1 (PD-1), on responses and disease control in patients with advanced or refractory alveolar soft part sarcoma: Results from a phase 1 trial.

2018

Sheng Yang
Jianliang Yang
Xiaohong Han
Ying Han
Shiyu Jiang
Jiarui Yao
Zhishang Zhang
Shuxiang Zhang
Peng Liu
Yan Qin
Hui Feng
Sheng Yao
Sun Y
Yuankai Shi

11572Background: Alveolar soft part sarcoma (ASPS) is a rare and lethal malignancy mainly affecting youth, with no effective standard systemic treatment. Checkpoint inhibitors has showed efficacy i...

Keywords:

Alveolar soft part sarcoma
Pathology
Immunology
Disease
Monoclonal antibody
Medicine
disease control
Malignancy
Refractory
in patient
immune checkpoint inhibitors
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations